作者
George Papatheodoridis, George Dalekos, Vana Sypsa, Cihan Yurdaydin, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis, Onur Keskin, Savvoula Savvidou, Juan De La Revilla, Bettina E Hansen, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry LA Janssen, Pietro Lampertico
发表日期
2016/4/1
期刊
Journal of hepatology
卷号
64
期号
4
页码范围
800-806
出版商
Elsevier
简介
Background & Aims
Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort study aimed to develop and validate an accurate HCC risk score in Caucasian CHB patients treated with the current oral antivirals, entecavir/tenofovir.
Methods
We included 1815 adult Caucasians with CHB and no HCC at baseline who received entecavir/tenofovir for ⩾12 months. Using data from eight centers (derivation dataset, n = 1325), a HCC risk score was developed based on multivariable Cox models and points system for simplification. Harrell’s c-index was used as discrimination, bootstrap for internal validation and the data from the 9th and largest center (validation dataset, n = 490) for external validation.
Results
The 5-year cumulative HCC incidence rates were 5.7% and 8.4% in the derivation and …
学术搜索中的文章
G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin… - Journal of hepatology, 2016